Nephrotic Syndrome Treatment Market Size, Emerging Drugs, Market Outlook, and Companies 2034

DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Nephrotic Syndrome Market by downloading the comprehensive report from DelveInsight @ Nephrotic Syndrome Therapeutics Market- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Nephrotic Syndrome Market Report
• In October 2024:- Hoffmann-La Roche- This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
• In October 2024:- Sanofi- This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years.
• The increase in Nephrotic Syndrome Market Size is a direct consequence of expected launch of potential therapies, along with great competition among various companies and precision approach that will lead to the development of more effective therapies.
• The total Nephrotic Syndrome diagnosed prevalent cases in the 7MM were 786,336 in 2022. These Nephrotic Syndrome cases in the 7MM are expected to increase throughout the study period, i.e., 2019-2032.
• The leading Nephrotic Syndrome Companies working in the market include GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others.
• Promising Nephrotic Syndrome Pipeline Therapies in the various stages of development include Mizoribine (MZR), Cyclophosphamide (CTX), Obinutuzumab, Prednisone, Tacrolimus, and others.

Gain a competitive edge in the Nephrotic Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Nephrotic Syndrome Treatment Drugs- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nephrotic Syndrome Epidemiology Segmentation in the 7MM
• Total Nephrotic Syndrome Diagnosed Prevalent Cases
• Nephrotic Syndrome Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Nephrotic Syndrome Epidemiology trends @ Nephrotic Syndrome Epidemiological Insights- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nephrotic Syndrome Market Insights
Nephrotic syndrome is a collection of symptoms that signal impaired kidney function. These symptomsen compass proteinuria, hypoalbuminemia, edema, hyperlipidemia, and various other associatedcomplications. The management of nephrotic syndrome entails addressing underlying medical conditions contributing to itsonset. Healthcare professionals may prescribe medications and dietary modifications to regulate symptomsand address complications associated with nephrotic syndrome. Currently, there are no authorized therapiesspecifically designed for treating nephrotic syndrome, and the predominant treatment strategies often involveoff-label approaches. Corticosteroids like prednisone, cyclophosphamide, and cyclosporine are employed toinduce remission in nephrotic syndrome. Diuretics are utilized to alleviate edema, whileangiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor blockers are employed to diminish proteinuria.

Nephrotic Syndrome Treatment Landscape
there are approved medications targeting specific causes of Nephrotic syndrome. For instance, in the case of lupus nephritis, BENLYSTA (belimumab),a humanmonoclonal antibody, and LUPKYNIS (voclosporin), a calcineurin inhibitor with potent immunosuppressive properties, have received regulatory approval. In the context of IgA nephropathy, specific FDA-approved drugs include FILSPARI (Sparsentan), characterized as a dual endothelin angiotensin receptor antagonist (DEARA),and TARPEYO (Nefecon), categorized as a corticosteroid. Both are small molecules indicated for the treatment of IgA nephropathy. Additionally, INVOKANA (Canagliflozin)-a sodium-glucose cotransporter 2 (SGLT2) inhibitor-is an FDA-approved medication for addressing diabetic nephropathy.

Discover key developments and opportunities in the Nephrotic Syndrome Market. Click here to learn more from DelveInsight's latest report @ Nephrotic Syndrome Market Size- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nephrotic Syndrome Therapeutics Landscape
Nephrotic syndrome is a heterogeneous condition with various underlying causes, and responses to treatments can vary widely among individuals. Advancements in personalized medicine, tailoring treatments based on an individual's genetic makeup, biomarker profiles, and disease characteristics, could improve outcomes. Some of the promising drugs that are currently under development include potential drugs like Chinook Therapeutics' Atrasentan and Zigakibart (BION-1301), Roche's (Obinutuzumab, RG7159, GA101), Vera Therapeutics' Atacicept, Travere Therapeutics 'FILSPARI (Sparsentan) and others covering the treatment domain of nephrotic syndrome and associated causes. These drugs are expected to drive the market in the forecast period (2024-2034).

Nephrotic Syndrome Drugs Uptake
• Inaxaplin (VX-147) by Vertex Pharmaceuticals, formerly known as VX-147, is an oral, small molecule Apolipoprotein L1 (APOL1) inhibitor being developed by Vertex Pharmaceuticals to treat APOL1-mediated FSGS and other proteinuric kidney diseases. VX-147 is the first investigational treatment targeting the underlying cause of APOL1-mediated kidney disease (AMKD). Currently, the company is conducting a Phase II/III clinical trial for treating APOL1-mediated kidney disease. Additionally, a Phase I trial is ongoing in patients with renal impairment.

• Atrasentan by Chinook Therapeutics/ Novartis is an oral potent and selective endothelin A (ETA) receptor antagonist, which works by inhibiting the ETA receptor activation of multiple renal cell types. This blockade reduces kidney inflammation and fibrosis, thus leading to reduced proteinuria in patients with chronic kidney disease. Recently, the company posted interim results for its Phase III registration trial (ALIGN) for IgA nephropathy. Additionally, a Phase II open-label basket trial (AFFINITY) of proteinuria glomerular diseases, including IgA nephropathy, FSGS, Alport syndrome, and diabetic kidney disease (DKD), and a Phase II crossover trial (ASSIST) for individuals with IgA nephropathy on stable doses of a renin-angiotensin system inhibitor (RASi) and an SGLT2 inhibitor (SGLT2i) is also being conducted.

• Zetomipzomib (KZR-616) by Kezar Life Sciences is a first-in-class, selective immunoproteasome inhibitor for a range of autoimmune diseases. Immunoproteasomes play an important role in regulating the normal function of the immune system, and when inhibited, multiple pathways involved in inflammatory cytokine production and immune effector cell activity, including macrophages, B cells, and T cells, are also inhibited since the pathways regulated by immunoproteasomes are involved in the pathogenesis of many autoimmune diseases.

Download DelveInsight's Nephrotic Syndrome Market report today and stay ahead in this rapidly evolving field. @ Nephrotic Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Nephrotic Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Nephrotic Syndrome Companies- GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others.
• Nephrotic Syndrome Pipeline Therapies- Mizoribine (MZR), Cyclophosphamide (CTX), Obinutuzumab, Prednisone, Tacrolimus, and others.
• Nephrotic Syndrome Market Dynamics: Nephrotic Syndrome Market Drivers and Barriers

Discover more about Nephrotic Syndrome Drugs in development @ Nephrotic Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Nephrotic Syndrome Market Overview at a Glance
4. Epidemiology and Market Methodology of Nephrotic Syndrome
5. Executive Summary of Nephrotic Syndrome
6. Key Events
7. Nephrotic Syndrome: Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Therapies
12. Nephrotic Syndrome: Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

List of Top Selling Market Research Reports in 2024

• hip replacement devices market - https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
• diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• radial artery compression device market- https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
• sepsis market- https://www.delveinsight.com/report-store/sepsis-market
• spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
• transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-treatment-market
• bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
• vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
• healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
• wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
• artificial disc market- https://www.delveinsight.com/report-store/artificial-disc-market
• microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
• brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
• healthcare consulting solutions- https://www.delveinsight.com/consulting
• skin neoplasm market- https://www.delveinsight.com/blog/skin-cancer-treatment-market-and-key-companies
• vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
• myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myelofibrosis-mf-market
• orthopedic splints device market- https://www.delveinsight.com/report-store/orthotic-devices-market
• total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
• lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-epidemiology-forecast

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.